Market Research Logo

Erythropoietin Market in Japan 2015-2019

About erythropoietin

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key vendors

  • Chugai Pharmaceutical
  • JCR Pharmaceuticals
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
Other prominent vendors
  • Eisai
  • Otsuka
  • Taiho Pharmaceutical
  • Takeda
Market driver
  • Increased incidence of anemia due to illness
  • For a full, detailed list, view our report
Market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Market trend
  • Strategic alliances
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Erythropoietin Drugs Market in Japan 2015-2019

Technavio recognizes the following companies as the key players in the Erythropoietin Drugs Market in Japan: Chugai Pharmaceutical, JCR Pharmaceuticals, Kissei Pharmaceutical and Kyowa Hakko Kirin



Commenting on the report, an analyst from Technavio’s team said: “Biosimilars are more cost-effective than branded erythropoietin drugs. The favorable regulatory scenario in Japan increases the focus of pharmaceutical companies on the development of biosimilars. After the implementation of the new regulatory framework for biosimilars in March 2009, seven biosimilar products have been approved in the country. In addition, patent expiries of branded biologics provide significant opportunities for vendors to develop their corresponding biosimilars. For instance, Epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar form of epoetin alfa that was launched in the market in May 2010.”

According to the report, kidney diseases, cancer, and HIV can cause anemia in people. The kidneys of individuals with chronic kidney disease do not function normally due to the decrease in the levels of erythropoietin. Such patients have a deficiency of iron, vitamin B12, and folic acid, which are essential for the formation of hemoglobin by red blood cells. This leads to anemia in patients. The condition is aggravated in individuals with dysfunctional kidneys who require dialysis. About 80% of such individuals undergo erythropoietin therapy for the treatment of anemia. The Japanese Society for Dialysis Therapy reported that the number of people who require dialysis patients is increasing every year in the country.

Further, the report states that erythropoietin drugs are expensive and unaffordable to many people.

Companies Mentioned

Chugai Pharmaceutical, JCR Pharmaceuticals, Kissei Pharmaceutical, Kyowa Hakko Kirin

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Biosimilars and biologics industry
    • Overview
      • Table Definition of biosimilars by organizations
    • Emerging role of biosimilars
    • Factors influencing biosimilars and biologics industry
      • Table Factors influencing biosimilars and biologics industry
      • Table Patent expiries of branded biologics
      • Table Impact of biosimilar cost savings on various sectors
    • Biosimilars: Business and pricing strategy
      • Table Factors affecting success of biosimilars
    • Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies
      • Table Biosimilars industry: Point-of-view
  • Japan: Country snapshot
    • Pharmaceutical industry in Japan
      • Table Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
      • Table Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
      • Table Japan's percentage share in world imports of pharmaceuticals 2013
      • Table Japan's percentage share in world exports of pharmaceutical 2013
    • Biosimilars and biologics industry in Japan
      • Table Biosimilars approved by PMDA in Japan
    • Regulatory landscape
      • Table Review process of biosimilars in Japan
    • Healthcare reforms
    • Erythropoietin: Addressable market in Japan
      • Table Number of people with cancer in Japan 2010-2013
      • Table Incidence of cancers in Japan 2011
  • Global erythropoietin drugs market
    • Table Approved erythropoietin biosimilars
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Erythropoietin drugs market in Japan 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by application
    • End-stage renal disease
    • Cancer
    • HIV
    • Wounds and neural disease
  • Market segmentation by product
    • First-generation erythropoietin formulation
    • Second-generation erythropoietin formulation
    • Biosimilars
  • Market segmentation by end-user
    • Hospitals
    • Pharmacies
      • Table Erythropoietin drugs market in Japan by end-user 2014
      • Table Erythropoietin drugs market in Japan by product in hospitals 2014
      • Table Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
  • Market drivers
    • Increased incidence of anemia
      • Table Number of people receiving dialysis in Japan 2008-2012
    • Reimbursement for erythropoietin preparations
    • Favorable growth opportunities
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Complex manufacturing process
    • Complicated regulatory framework
    • Physician's reluctance to prescribe biosimilars
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Strategic alliances
    • Increased R&D of innovative molecule drugs
    • Focus on biosimilars
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
      • Table Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
      • Table Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
      • Table Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
      • Table JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
      • Table Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
  • Key vendor analysis
    • Chugai Pharmaceutical
      • Table Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
      • Table Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
    • JCR Pharmaceuticals
    • Kissei Pharmaceutical
      • Table Kissei Pharmaceutical: Business segmentation by revenue 2015
      • Table Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
      • Table Kissei Pharmaceutical: Geographical segmentation by revenue 2015
    • Kyowa Hakko Kirin
      • Table Kyowa Hakko Kirin: Business segmentation by revenue 2014
      • Table Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
      • Table Kyowa Hakko Kirin: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report